PL1994055T3 - Przeciwciała anty-5T4 i ich zastosowanie - Google Patents

Przeciwciała anty-5T4 i ich zastosowanie

Info

Publication number
PL1994055T3
PL1994055T3 PL07758256T PL07758256T PL1994055T3 PL 1994055 T3 PL1994055 T3 PL 1994055T3 PL 07758256 T PL07758256 T PL 07758256T PL 07758256 T PL07758256 T PL 07758256T PL 1994055 T3 PL1994055 T3 PL 1994055T3
Authority
PL
Poland
Prior art keywords
antibodies
Prior art date
Application number
PL07758256T
Other languages
English (en)
Inventor
Erwin R Boghaert
Nitin K Damle
Philip Ross Hamann
Kiran Khandke
Arthur Kunz
Kimberly A Marquette
Lioudmila Tchistiakova
Davinder Gill
Kodangattil Raman Sreekumar
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38445207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1994055(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL1994055T3 publication Critical patent/PL1994055T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PL07758256T 2006-03-10 2007-03-09 Przeciwciała anty-5T4 i ich zastosowanie PL1994055T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78134606P 2006-03-10 2006-03-10
US89124807P 2007-02-23 2007-02-23
PCT/US2007/063685 WO2007106744A2 (en) 2006-03-10 2007-03-09 Anti-5t4 antibodies and uses thereof
EP07758256.7A EP1994055B1 (en) 2006-03-10 2007-03-09 Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PL1994055T3 true PL1994055T3 (pl) 2015-02-27

Family

ID=38445207

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07758256T PL1994055T3 (pl) 2006-03-10 2007-03-09 Przeciwciała anty-5T4 i ich zastosowanie

Country Status (30)

Country Link
US (5) US8044178B2 (pl)
EP (3) EP2368914B1 (pl)
JP (1) JP5523824B2 (pl)
KR (2) KR101443752B1 (pl)
CN (1) CN101437850B (pl)
AR (1) AR059809A1 (pl)
AU (1) AU2007226696C1 (pl)
BR (1) BRPI0708771B8 (pl)
CA (1) CA2645097C (pl)
CR (1) CR10273A (pl)
DK (2) DK1994055T3 (pl)
EC (1) ECSP088733A (pl)
ES (2) ES2712942T3 (pl)
GT (1) GT200800181A (pl)
HK (1) HK1121473A1 (pl)
IL (2) IL193986A (pl)
MX (1) MX2008011492A (pl)
MY (1) MY148763A (pl)
NO (1) NO20083891L (pl)
NZ (2) NZ596295A (pl)
PA (1) PA8718601A1 (pl)
PE (1) PE20080119A1 (pl)
PL (1) PL1994055T3 (pl)
PT (1) PT1994055E (pl)
SA (1) SA07280101B1 (pl)
SG (1) SG170091A1 (pl)
SI (1) SI1994055T1 (pl)
TW (2) TWI421257B (pl)
WO (1) WO2007106744A2 (pl)
ZA (1) ZA200808075B (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978985A2 (en) * 2005-12-23 2008-10-15 Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting hdgf
DK1994055T3 (da) * 2006-03-10 2014-08-25 Wyeth Llc Anti-5t4-antistoffer og anvendelser deraf
PL2064325T3 (pl) 2006-09-01 2012-05-31 Therapeutic Human Polyclonals Inc Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek
ES2405605T3 (es) 2009-03-27 2013-05-31 Wyeth Llc Células iniciadoras de tumores y procedimientos de uso de las mismas
GB0918383D0 (en) * 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
JP2013523153A (ja) 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
US9592331B2 (en) 2011-02-07 2017-03-14 Aggamin Llc Methods and systems for treating eclampsia or pre-eclampsia
CA2830338C (en) 2011-04-01 2016-11-15 Wyeth Llc Antibody-drug conjugates
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
AU2013213301A1 (en) 2012-01-24 2014-07-17 Epic Sciences, Inc. Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
AU2013359167B2 (en) 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
WO2014137931A1 (en) * 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
CA2915960A1 (en) * 2013-06-17 2014-12-24 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
CN105813655B (zh) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
AU2014331714B2 (en) 2013-10-11 2019-05-02 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
KR20160072268A (ko) 2013-11-04 2016-06-22 화이자 인코포레이티드 항-efna4 항체-약물 접합체
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
HUE056023T2 (hu) 2014-05-22 2022-01-28 Byondis Bv Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k
CN113549153A (zh) 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
JP6721568B2 (ja) 2014-07-29 2020-07-15 セレクティスＣｅｌｌｅｃｔｉｓ がん免疫療法のためのｒｏｒ１（ｎｔｒｋｒ１）特異的キメラ抗原レセプター
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
AU2015310897B2 (en) 2014-09-04 2020-03-19 Cellectis Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
US20160251417A1 (en) * 2015-01-22 2016-09-01 Prothena Biosciences Limited Antibodies recognizing medin
WO2016185035A1 (en) 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
NZ740686A (en) 2015-09-18 2021-12-24 Arch Oncology Inc Therapeutic cd47 antibodies
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
SG11201803692PA (en) * 2015-11-24 2018-06-28 Synthon Biopharmaceuticals Bv Anti-5t4 antibodies and antibody-drug conjugates
CN110606890B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
AU2017299581A1 (en) * 2016-07-20 2019-01-17 EyePoint Pharmaceuticals, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN108084265B (zh) * 2016-11-23 2021-07-02 复旦大学 特异性结合人的5t4抗原的全人源单域抗体及其应用
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11427645B2 (en) 2017-03-15 2022-08-30 Oxford Biomedica (Uk) Limited 5T4-targeting agents and methods
US11608384B2 (en) 2017-04-05 2023-03-21 Xdcexplorer (Shanghai) Co., Ltd. Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
WO2018226795A1 (en) * 2017-06-06 2018-12-13 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof
CN111148763B (zh) 2017-07-20 2023-11-03 Aptevo研究与开发公司 结合于5t4和4-1bb的抗原结合蛋白以及相关组合物和方法
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
MX2020007024A (es) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
MA52152A (fr) 2018-03-12 2021-01-20 Genmab As Anticorps
US20190330366A1 (en) 2018-04-11 2019-10-31 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
US20200048350A1 (en) 2018-07-24 2020-02-13 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Monodomain antibodies of cd28 and their multivalent and multispecific constructs
WO2022087416A1 (en) * 2020-10-22 2022-04-28 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
JP2024501771A (ja) * 2021-01-06 2024-01-15 パレオン ファーマシューティカルズ インコーポレイテッド 抗ｐｄ－ｌ１抗体及びその融合タンパク質
WO2023155925A1 (en) * 2022-02-21 2023-08-24 Concept To Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5952329A (en) 1996-01-23 1999-09-14 The General Hospital Corporation Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
WO1998055607A2 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
WO2000029428A2 (en) 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7402666B2 (en) * 2000-11-13 2008-07-22 Oxford Biomedica (Uk) Ltd. Nucleotide encoding canine 5T4 antigen
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
HUE030806T2 (hu) 2002-05-02 2017-05-29 Wyeth Holdings Llc Calicheamicin származék-hordozó konjugátumok
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2006004950A2 (en) 2004-06-30 2006-01-12 International Bioimmune Systems, Inc. Humanized monoclonal antibody 31.1 as an anticancer agent
PA8645301A1 (es) 2004-09-10 2006-07-03 Wyeth Corp Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
AU2005294373B2 (en) * 2004-10-05 2011-12-08 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
DK1994055T3 (da) * 2006-03-10 2014-08-25 Wyeth Llc Anti-5t4-antistoffer og anvendelser deraf
UA112291C2 (uk) 2010-04-21 2016-08-25 Синтарґа Б.В. Кон'югати аналогів cc-1065 і біфункціональні лінкери
CA2830338C (en) * 2011-04-01 2016-11-15 Wyeth Llc Antibody-drug conjugates

Also Published As

Publication number Publication date
DK1994055T3 (da) 2014-08-25
CA2645097A1 (en) 2007-09-20
GT200800181A (es) 2010-05-25
ECSP088733A (es) 2008-10-31
BRPI0708771A2 (pt) 2011-06-14
RU2008137074A (ru) 2010-04-20
CA2645097C (en) 2019-09-17
WO2007106744A8 (en) 2008-10-02
NO20083891L (no) 2008-12-03
IL193986A0 (en) 2011-08-01
US20070231333A1 (en) 2007-10-04
JP5523824B2 (ja) 2014-06-18
PA8718601A1 (es) 2009-05-15
IL240245A0 (en) 2015-09-24
CN101437850A (zh) 2009-05-20
US9902771B2 (en) 2018-02-27
CN101437850B (zh) 2013-10-09
DK2368914T3 (en) 2019-03-04
EP1994055B1 (en) 2014-07-02
US20180162937A1 (en) 2018-06-14
SI1994055T1 (sl) 2014-08-29
ES2712942T3 (es) 2019-05-16
KR101264216B1 (ko) 2013-05-31
KR20130018980A (ko) 2013-02-25
TWI409277B (zh) 2013-09-21
NZ571208A (en) 2011-12-22
US8044178B2 (en) 2011-10-25
AU2007226696B2 (en) 2013-08-29
NZ596295A (en) 2013-01-25
PT1994055E (pt) 2014-09-15
TW200804424A (en) 2008-01-16
EP1994055A2 (en) 2008-11-26
US20140308302A1 (en) 2014-10-16
MY148763A (en) 2013-05-31
ZA200808075B (en) 2012-03-28
AR059809A1 (es) 2008-04-30
JP2009529578A (ja) 2009-08-20
EP2368914B1 (en) 2019-01-02
BRPI0708771B1 (pt) 2019-10-22
BRPI0708771B8 (pt) 2021-05-25
KR20080106345A (ko) 2008-12-04
KR101443752B1 (ko) 2014-09-26
SA07280101B1 (ar) 2011-10-03
AU2007226696A1 (en) 2007-09-20
WO2007106744A2 (en) 2007-09-20
MX2008011492A (es) 2008-09-22
ES2498517T3 (es) 2014-09-24
HK1121473A1 (en) 2009-04-24
TWI421257B (zh) 2014-01-01
TW201335189A (zh) 2013-09-01
EP2368914A1 (en) 2011-09-28
WO2007106744A3 (en) 2007-11-29
EP3539989A1 (en) 2019-09-18
IL193986A (en) 2015-08-31
US20160185859A1 (en) 2016-06-30
US20120064600A1 (en) 2012-03-15
US8759495B2 (en) 2014-06-24
PE20080119A1 (es) 2008-03-04
AU2007226696C1 (en) 2016-02-04
CR10273A (es) 2008-11-26
IL240245A (en) 2017-05-29
SG170091A1 (en) 2011-04-29

Similar Documents

Publication Publication Date Title
IL240245A (en) 5t4 antibodies and their uses
IL272883A (en) Monoclonal antibodies and their uses
ZA200810311B (en) Anti-NKG2A antibodies and uses thereof
IL196397A0 (en) Prlr-specific antibody and uses thereof
PL2099826T3 (pl) Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL222922A (en) Antibodies against neurophilin-1 and their use
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL184024A0 (en) Irta-5 antibodies and their uses
IL231891A (en) Anti-ephrinb2 antibodies and methods for their use
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE
IL212731A0 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
ZA200905136B (en) Anti-robo4 antibodies and uses therefor
ZA200705716B (en) IRTA-2 antibodies and their uses